Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis
This study has been terminated.
( Interim analysis, infliximab did not reduce number of first relapses in GCA or cumulative glucocorticosteroid dosage )
Study NCT00076726.   Last updated on April 18, 2008.
Information provided by Centocor, Inc.
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Giant Cell Arteritis
Additional conditions recognized in this trial
Arteritis
Polymyalgia Rheumatica
More general conditions related to this trial
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Brain Diseases
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Connective Tissue Diseases
Immune System Diseases
Muscular Diseases
Musculoskeletal Diseases
Nervous System Diseases
Rheumatic Diseases
Skin Diseases
Skin Diseases, Vascular
Vascular Diseases
Vasculitis
Vasculitis, Central Nervous System
Interventions listed in this trial
Infliximab
More general drug interventions related to this trial
Anti-Inflammatory Agents
Antirheumatic Agents
Dermatologic Agents
Gastrointestinal Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Centocor, Inc.
The Cleveland Clinic
International Network for the Study of Systematic Vasculitides


U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services